A single-arm, phase II study of neoadjuvant MPDL3280A, nab-paclitaxel and carboplatin (MAC) in resectable non-small cell lung cancer (NSCLC)
||Genentech, Inc., Celgene Corporation
||Male and Female Patients
|U.S. Govt. ID:
||Research Nurse Navigator: 212-342-5162 / firstname.lastname@example.org
This study is for patients who are being considered for surgical removal of a specific kind of lung cancer called "non-small lung cancer" (NSCLC), which is a description of the way it looks under a microscope. The purpose of this study is to determine whether adding an investigational treatment called atezolizumab (also called MPDL3280A) to standard chemotherapy before surgery will result in additional shrinking of the cancer.
This study is closed
Catherine Shu, MD
|Have you been diagnosed with Non-Small-Cell Lung Cancer?